Printer Friendly

EDITEK, INC. SUCCESSFULLY COMPLETES DEVELOPMENT OF SEVERAL TESTS FOR U.S. DEPARTMENT OF DEFENSE

 BURLINGTON, N.C., March 29 /PRNewswire/ -- EDITEK, Inc., (AMEX: EDI.EC) reported today that is has completed test development for the detection of certain agents of biological origin in environmental samples for the United States Department of Defense. The Company has completed development of multiple step EZ-SCREEN(R) tests for Botulinum Toxins A and B, "B anthracis," Staphylococcal Enterotoxin B and Ricin Toxin while work continues on a test for Botulinum E Toxin. Tests for Botulinum Toxins A and B and for Staphylococcal Enterotoxin B have been successfully transitioned to the one-step RECON(TM) format. Conversion of the "B anthracis" test to the one-step RECON format is now in progress.
 Development of individual tests for additional agents/toxins is planned. The ultimate goal of the project is to create a device slightly larger than a silver dollar that would incorporate up to eight individual RECON one-step tests. This would provide individual tests for specific agent/toxin groups on a single device within ten minutes following sample addition.
 Dr. Golden, who has led the EDITEK research and development effort for the DOD project, said, "Our research and product development team has overcome significant challenges in the development of these sensitive, accurate and specific on-site test -- particularly the RECON one-step tests. These tests are now available and are being provided to the Department of Defense. I am proud of our research team which has been able to complete the development of these tests ahead of schedule and under budget."
 EDITEK, Inc. is an emerging, biodiagnostic company with patented technology for the performance of rapid, on-site assays including one- step assays. The Company currently sells products for the human/clinical, drugs of abuse and agridiagnostics/food safety testing markets. EDITEK also has a research, development and supply agreement with Farnam Companies for veterinary diagnostics.
 -0- 3/29/93
 /CONTACT: Peter Heath, Vice President-Finance and Chief Financial Officer, EDITEK, Inc., 919-226-6311/
 (EDI)


CO: EDITEK, Inc.; United States Department of Defense ST: North Carolina IN: CHM SU:

MM -- CH008 -- 0631 03/29/93 15:27 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 29, 1993
Words:341
Previous Article:SCIENTIFIC-ATLANTA SELECTED FOR SECOND PHASE OF THE U.S. ARMY'S OBSERVE PROGRAM
Next Article:DIBRELL AND STANDARD COMMERICAL COMBINED SALES OF $2.3 BILLION
Topics:


Related Articles
EDITEK LAUNCHES VERDICT ONE-STEP CANNABINOID TEST
EDITEK, INC. ANNOUNCES SECOND QUARTER RESULTS
EDITEK, INC. GRADUATES TO AMERICAN STOCK EXCHANGE PRIMARY MARKET
EDITEK ESTABLISHES NEW BANKING RELATIONSHIP AND $1,000,000 LINE OF CREDIT
EDITEK ANNOUNCES ANNUAL MEETING DATE
EDITEK, INC. MARKETS NEW QUANTITATIVE AFLATOXIN TEST EZ-QUANT
EDITEK, INC. RECEIVES SIGNIFICANT CONTRACT MODIFICATION FOR TEST DEVELOPMENT AND PRODUCTION FROM U.S. DEPARTMENT OF DEFENSE
EDITEK, INC. ENTERS INTO RESEARCH PROGRAM WITH BATTELLE MEMORIAL INSTITUTE
EDITEK, INC. CONSOLIDATES LABORATORY SERVICES AND WILL REALIZE SIGNIFICANT SAVINGS
Lockheed Martin Team Successfully Tests Thruster for Missile Defense Agency's Multiple Kill Vehicle.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters